Decaprenyl-phosphoryl-ribose 2′-epimerase (DprE1): Challenging target for antitubercular drug discovery

40Citations
Citations of this article
106Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Tuberculosis has proved harmful to the entire history of mankind from past several decades. Decaprenyl-phosphoryl-ribose 2′-epimerase (DprE1) is a recent target which was identified in 2009 but unfortunately it is neither explored nor crossed phase II. In past several decades few targets were identified for effective antitubercular drug discovery. Resistance is the major problem for effective antitubercular drug discovery. Arabinose is constituent of mycobacterium cell wall. Biosynthesis of arabinose is FAD dependant two step epimerisation reaction which is catalysed by DprE1 and DprE2 flavoprotein enzymes. The current review is mainly emphases on DprE1 as a perspective challenge for further research.

Cite

CITATION STYLE

APA

Gawad, J., & Bonde, C. (2018). Decaprenyl-phosphoryl-ribose 2′-epimerase (DprE1): Challenging target for antitubercular drug discovery. Chemistry Central Journal. BioMed Central Ltd. https://doi.org/10.1186/s13065-018-0441-2

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free